SCHEMBL538655

SCHEMBL538655

COc1ccc(CN2CCC3NNc4nc(NCCN5CCOCC5)nc2c43)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 2/20 0.45
MTOR P42345 2/20 0.45
MAPK1 P28482 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
EGFR P00533 1/20 0.41
RAB9A P51151 2/20 0.41
PDE5A O76074 2/20 0.40
BACE1 P56817 2/20 0.40
LMNA P02545 2/20 0.39
BRD4 O60885 1/20 0.39
CREBBP Q92793 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.38
MEN1 O00255 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
KDM1A O60341 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2812174 0.89 LMNA (0.51) PIK3CAMTORHPGDRAB9ABACE1
SCHEMBL2809870 0.86 PIK3CA (0.46) PIK3CAMTORMAPK1SMN1; SMN2MAPT
SCHEMBL2814505 0.84 KDM1A (0.46) MAPK1SMN1; SMN2MAPTHPGDRAB9A
SCHEMBL2810273 0.84 ADORA3 (0.41) SMN1; SMN2MAPTHPGDBACE1KDM4E
SCHEMBL2813941 0.84 ADORA3 (0.41) SMN1; SMN2MAPTHPGDBACE1KDM4E
SCHEMBL2809367 0.83 CNR2 (0.40) SMN1; SMN2MAPTEGFRLMNAKDM4E
SCHEMBL2812312 0.83 LMNA (0.45) PIK3CAMTORMAPK1SMN1; SMN2MAPT
SCHEMBL2812933 0.83 CLK4 (0.41) SMN1; SMN2MAPTBACE1LMNAALDH1A1
SCHEMBL537584 0.83 ACHE (0.45) MAPTBACE1MEN1KMT2AEHMT2
SCHEMBL2812056 0.82 CXCR3 (0.37) MAPTBACE1KDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2414359-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ArQule, Inc. (US) 2012-02-08 EP claimed
WO-2010114905-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-10-07 WO claimed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS DPYD, TYMP, TP53 PIK3CA 74/4885MTOR 351/4885MAPK1 1997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.